NCT05946213ClinicalTrials.gov
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer
En resumen
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate…
Fase 31500 participantes buscados436 centros5 países
Categorías
Registrado en 1 registro
- ClinicalTrials.govNCT05946213Abrir este registro en ClinicalTrials.govSincronizado hace 4 semanas
Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.
La información del ensayo se muestra tal como la publicó el registro, en su idioma original.
¿Le interesa este estudio?
Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2023-07-14; recorded start 2023-12-14
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 51 other studies in this databaseCounted from the lead sponsor named in the record (NRG Oncology)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 3 conditions.
- Lead sponsor type recorded as: other.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding0/20
Open-label
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 413 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 1,500 participants (target), run at 436 sites, across 5 countries.
How this score is built
- Enrolment31/40
1,209 participants (target)
- Site count25/25
413 sites
- Country count7/15
4 countries
- Planned duration10/10
Planned over about 150 months
- Sponsor scale6/10
NRG Oncology has led 49 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Resumen
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Afecciones
- Prostate Adenocarcinoma
- Stage III Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
Elegibilidad
| Sexo | Hombre |
|---|---|
| Edades | 18 Years – Sin máximo |
| Voluntarios sanos | No |
Elegibilidad tal como figura en el registro
Elegibilidad en frases sencillas
Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.
Diseño del estudio
| Tipo de estudio | De intervención |
|---|---|
| Fase | Fase 3 |
| Asignación | Aleatorizado |
| Modelo de intervención | PARALLEL |
| Propósito principal | TREATMENT |
| Enmascaramiento | NONE (0) |
| Inscripción | 1500 participantes buscados |
Patrocinador y colaboradores
- NRG Oncology Patrocinador
Grupos e intervenciones
- Arm I (SBRT)EXPERIMENTAL
Patients undergo SBRT for a total of 5 treatments over 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan and/or CT, MRI, or PET/CT during screening and CT and/or MRI on study. Additionally, patients may optionally undergo blood and urine sample collection on study.
- Arm II (EBRT)ACTIVE_COMPARATOR
Patients undergo EBRT for 20 to 45 treatments over 4 to 9 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan and/or CT, MRI, or PET/CT during screening and CT and/or MRI on study. Additionally, patients may optionally undergo blood and urine sample collection on study.
Intervenciones
- Procedimiento Biospecimen Collection
Undergo blood and urine sample collection
- Procedimiento Bone Scan
Undergo bone scan
- Procedimiento Computed Tomography
Undergo CT or PET/CT
- Radiación External Beam Radiation Therapy
Undergo EBRT
- Procedimiento Magnetic Resonance Imaging
Undergo MRI
- Procedimiento Positron Emission Tomography
Undergo PET/CT
- Otro Quality-of-Life Assessment
Ancillary studies
- Otro Questionnaire Administration
Ancillary studies
- Radiación Stereotactic Body Radiation Therapy
Undergo SBRT
Variables de resultado
Variable de resultado principal
Metastasis-free survival (MFS)
Based on conventional imaging. Median MFS time comparing the curves.
Plazo From randomization to the date of distant metastasis, or death from any cause, assessed up to 15 years
Variable de resultado secundaria
Failure-free survival
Median failure-free survival time comparing the curves.
Plazo From randomization to the date of distant metastasis, or death from any cause, assessed up to 15 years
Variable de resultado secundaria
Overall survival
Median survival time comparing the curves.
Plazo From the date of randomization to the date of death or last known follow-up date, with patients alive at the last known follow-up time treated as censored, assessed up to 15 years
Variable de resultado secundaria
MFS
Median MFS time comparing the curves.
Plazo From randomization to the date of distant metastasis, or death from any cause, assessed up to 15 years
Variable de resultado secundaria
Incidence of adverse events (AEs)
AEs will be graded using National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5. Counts of all AEs by grade will be provided by treatment arm.
Plazo Up to 15 years
Variable de resultado secundaria
Urinary incontinence
Proportion of patients with a decline, as measured by the urinary incontinence domain of the Expanded Prostate Cancer Index Composite (EPIC-26).
Plazo Up to 5 years
Variable de resultado secundaria
Urinary irritative/obstructive
Proportion of patients with a decline, as measured by the urinary irritative/obstructive domain of the Expanded Prostate Cancer Index Composite (EPIC-26).
Plazo Up to 5 years
Variable de resultado secundaria
Bowel function
Proportion of patients with a decline, as measured by the bowel domain of the Expanded Prostate Cancer Index Composite (EPIC-26).
Plazo Up to 5 years
Variable de resultado secundaria
Fatigue
Proportion of patients with a decline, as measured by the Patient Reported Outcomes Measurement Information System-Fatigue.
Plazo Up to 5 years
Otra variable de resultado
Patient-reported outcomes
The EPIC-26 sexual domain will be assessed as an exploratory endpoint but following the analysis plan specified for the EPIC-26 urinary and bowel domains.
Plazo Up to 5 years
Otra variable de resultado
Cost
Measured by the Functional Assessment of Chronic Illness Therapy-COST.
Plazo Up to 1 year
Otra variable de resultado
Estimate of treatment effect by sex
Will estimate the primary outcome treatment effect and the corresponding 95% confidence intervals (CIs) by sex.
Plazo Up to 15 years
Otra variable de resultado
Estimate of treatment effect by race
Will estimate the primary outcome treatment effect and the corresponding 95% CIs by race.
Plazo Up to 15 years
Otra variable de resultado
Estimate of treatment effect by ethnicity
Will estimate the primary outcome treatment effect and the corresponding 95% CIs by ethnicity.
Plazo Up to 15 years
Fechas
| Fecha de inicio | 14 de diciembre de 2023 (real) |
|---|---|
| Finalización principal | 31 de marzo de 2036 (estimada) |
| Finalización | 31 de marzo de 2041 (estimada) |
| Primera publicación | 14 de julio de 2023 (real) |
| Última actualización | 23 de octubre de 2026 |
| Resultados publicados | No indicado en el registro |
| Estado verificado por última vez | octubre de 2026 |
Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.
Ubicaciones
431 centros están en reclutamiento
Canada
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| CHUM - Centre Hospitalier de l'Universite de Montreal | Montreal | Quebec | En reclutamiento |
| CIUSSSEMTL-Hopital Maisonneuve-Rosemont | Montreal | Quebec | En reclutamiento |
| The Research Institute of the McGill University Health Centre (MUHC) | Montreal | Quebec | En reclutamiento |
| Ottawa Hospital and Cancer Center-General Campus | Ottawa | Ontario | En reclutamiento |
| CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) | Québec | Quebec | En reclutamiento |
| Atlantic Health Sciences Corporation-Saint John Regional Hospital | Saint John | New Brunswick | En reclutamiento |
| Centre Hospitalier Universitaire de Sherbrooke-Fleurimont | Sherbrooke | Quebec | En reclutamiento |
| University Health Network-Princess Margaret Hospital | Toronto | Ontario | En reclutamiento |
| Odette Cancer Centre- Sunnybrook Health Sciences Centre | Toronto | Ontario | En reclutamiento |
Hong Kong
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Pamela Youde Nethersole Eastern Hospital | Chai Wan | Suspendido |
Singapore
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| National Cancer Centre Singapore | Singapore | En reclutamiento |
Switzerland
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Kantonsspital Aarau | Aarau | En reclutamiento |
United States
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Cleveland Clinic Akron General | Akron | Ohio | En reclutamiento |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | En reclutamiento |
| Alton Memorial Hospital | Alton | Illinois | En reclutamiento |
| American Fork Hospital / Huntsman Intermountain Cancer Center | American Fork | Utah | En reclutamiento |
| McFarland Clinic - Ames | Ames | Iowa | En reclutamiento |
| Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor | Michigan | En reclutamiento |
| University of Michigan Rogel Cancer Center | Ann Arbor | Michigan | En reclutamiento |
| Aspirus Cancer Care-Antigo-Volm Cancer Center | Antigo | Wisconsin | En reclutamiento |
| Kaiser Permanente-Deer Valley Medical Center | Antioch | California | En reclutamiento |
| Northwest Wisconsin Cancer Center | Ashland | Wisconsin | En reclutamiento |
| Duluth Clinic Ashland | Ashland | Wisconsin | En reclutamiento |
| Emory Proton Therapy Center | Atlanta | Georgia | En reclutamiento |
| Emory Saint Joseph's Hospital | Atlanta | Georgia | En reclutamiento |
| Grady Health System | Atlanta | Georgia | En reclutamiento |
| Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia | En reclutamiento |
| Emory University Hospital Midtown | Atlanta | Georgia | En reclutamiento |
| Advocate Outpatient Center - Aurora | Aurora | Illinois | En reclutamiento |
| UCHealth University of Colorado Hospital | Aurora | Colorado | En reclutamiento |
| Mount Sinai Comprehensive Cancer Center at Aventura | Aventura | Florida | En reclutamiento |
| UH Seidman Cancer Center at UH Avon Health Center | Avon | Ohio | En reclutamiento |
| University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland | En reclutamiento |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | En reclutamiento |
| Veterans Administration Medical Center-Baltimore | Baltimore | Maryland | En reclutamiento |
| Maryland Proton Treatment Center | Baltimore | Maryland | En reclutamiento |
| Advocate Good Shepherd Hospital | Barrington | Illinois | En reclutamiento |
| MaineHealth Coastal Cancer Treatment Center | Bath | Maine | En reclutamiento |
| Mary Bird Perkins Cancer Center | Baton Rouge | Louisiana | En reclutamiento |
| Bay Pines VA Healthcare System | Bay Pines | Florida | En reclutamiento |
| Northwell Health Imbert Cancer Center | Bay Shore | New York | En reclutamiento |
| UHHS-Chagrin Highlands Medical Center | Beachwood | Ohio | En reclutamiento |
| UPMC-Heritage Valley Health System Beaver | Beaver | Pennsylvania | En reclutamiento |
| UM Upper Chesapeake Medical Center | Bel Air | Maryland | En reclutamiento |
| Clara Maass Medical Center | Belleville | New Jersey | En reclutamiento |
| Nebraska Medicine-Bellevue | Bellevue | Nebraska | En reclutamiento |
| PeaceHealth Saint Joseph Medical Center | Bellingham | Washington | En reclutamiento |
| Sanford Joe Lueken Cancer Center | Bemidji | Minnesota | En reclutamiento |
| Saint Charles Health System | Bend | Oregon | En reclutamiento |
| Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners | Vermont | En reclutamiento |
En el registro figuran 386 centros más.
Documentos del estudio
No hay documentos enlazados en este registro.
Cambios a lo largo del tiempo
- 23 de octubre de 2026
Objetivo de inscripción modificado
Enrollment target revised up from 1209 to 1500
12091500
- 23 de octubre de 2026
Centro añadido
23 sites added (436 total)
413436